Impax announces shipment of authorized generic Zomig tablets and orally disintegrating tablets

Download PDF Copy

Editorial Checklist

Reviewed

Impax Laboratories, Inc.May 20 2013

NewsGuard 100/100 Score

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that its generics division, Global Pharmaceuticals, commenced shipment of authorized generic Zomig® (zolmitriptan) tablets and orally disintegrating tablets, 2.5 mg and 5 mg, in the U.S., as part of a Distribution, License, Development and Supply Agreement with AstraZeneca UK Limited (AstraZeneca).

Zomig® is indicated for the treatment of migraine headaches in adults. According to IMS Health data, U.S. sales of Zomig® tablets and orally disintegrating tablets were approximately $196 million in the 12 months ended April 2013.

Zomig® and Zomig-ZMT® are registered trademarks of the AstraZeneca group of companies.

Source:

Impax Laboratories, Inc.

Posted in: Medical Condition News | Pharmaceutical News

Tags: Migraine, Pharmaceuticals

Comments (0)

Download PDF Copy

Suggested Reading

Distinct immune profiles linked to adverse reactions from immunotherapy

Distinct immune profiles linked to adverse reactions from immunotherapy

Urine RNA analysis shows promise for detecting genitourinary diseases

Urine RNA analysis shows promise for detecting genitourinary diseases

SU2C announces grants to support cutting-edge research in a variety of cancers

SU2C announces grants to support cutting-edge research in a variety of cancers

Study highlights disparities in stroke burden across regions

Study highlights disparities in stroke burden across regions

Tiny molecule offers hope in reducing opioid side effects

Tiny molecule offers hope in reducing opioid side effects

Accelerating tobacco decline could boost global life expectancy

Accelerating tobacco decline could boost global life expectancy

Obesity medication liraglutide is safe and effective in children aged 6 to <12 years

Obesity medication liraglutide is safe and effective in children aged 6 to <12 years

Rising asthma rates in sub-Saharan Africa linked to urbanization and lack of care

Rising asthma rates in sub-Saharan Africa linked to urbanization and lack of care

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care